The Technical Analyst
IsoPlexis Corporation [ISO]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
IsoPlexis Corporation Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.762
America/New_York / 20 mar 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 30.28 mill |
| EPS: | -2.55 |
| P/E: | -0.299 |
| Earnings Date: | Nov 10, 2022 |
| SharesOutstanding: | 39.76 mill |
| Avg Daily Volume: | 0.0473 mill |
| RATING 2023-03-27 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.299 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.299 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.652 - 0.872 ( +/- 14.44%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-03-21 | Khakhar Rajesh T. | Sell | 14 583 | Common Stock |
| 2023-03-21 | Khakhar Rajesh T. | Sell | 40 000 | Stock Option |
| 2023-03-21 | Khakhar Rajesh T. | Sell | 31 600 | Stock Option |
| 2023-03-21 | Myers Jason W. | Sell | 40 000 | Stock Option |
| 2023-03-21 | Myers Jason W. | Sell | 89 047 | Stock Option |
| INSIDER POWER |
|---|
| -80.10 |
| Last 98 transactions |
| Buy: 16 662 811 | Sell: 5 848 053 |
Forecast:
01:40 - $0.909
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.762 (0.00% ) |
| Volume | 0.111 mill |
| Avg. Vol. | 0.0473 mill |
| % of Avg. Vol | 234.76 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ISO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ISO
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
Latest Press Releases
2023-02-24 08:00:00 - Press Release
Shareholder Alert: Weiss Law Reminds Iso, Argo, Osh, And Dct Shareholders About Its Ongoing Investigations
New york , feb. 24, 2023 /prnewswire/ -- if you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: joshua rubin, esq. weiss law305 broadway, 7th floor new york, ny 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com isoplexis corporation (nasdaq: iso) weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of isoplexis corporation (nasdaq: iso) in connection with its proposed acquisition by berkeley lights, inc. ("berkeley lights").
2023-02-14 17:50:00 - Press Release
Isoplexis Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Isoplexis Corporation - Iso
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of isoplexis corporation (nasdaqgs: iso) to berkeley lights, inc. (nasdaqgs: bli). under the terms of the proposed transaction, shareholders of isoplexis will receive 0.612 shares of berkeley lights for each share of isoplexis that they own.
2023-02-03 15:06:00 - Press Release
Shareholder Alert: Weiss Law Investigates Isoplexis Corporation
New york , feb. 3, 2023 /prnewswire/ -- weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of isoplexis corporation ("isoplexis" or the "company") (nasdaq: iso) in connection with its proposed acquisition by berkeley lights, inc. ("berkeley lights") (nasdaq: bli). under the merger agreement, the company's shareholders will receive 0.612 shares of berkeley lights common stock for each isoplexis share, representing implied per-share consideration of $1.44 based upon berkeley lights' february 2, 2023 closing price of $2.36.
2022-11-09 07:00:00 - Press Release
Isoplexis To Participate In Upcoming Investor Conferences
Branford, conn., nov. 09, 2022 (globe newswire) -- isoplexis corporation (nasdaq: iso), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the following investor conferences.
2022-10-19 07:00:00 - Press Release
Isoplexis To Report Third Quarter 2022 Financial Results On November 10, 2022
Branford, conn., oct. 19, 2022 (globe newswire) -- isoplexis corporation (nasdaq: iso), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on thursday, november 10, 2022. company management will be webcasting a corresponding conference call beginning at 5:30 a.m. pacific time / 8:30 a.m. eastern time.
Latest News
2022-12-22 10:22:23 - InvestorPlace
Why Is IsoPlexis (ISO) Stock Up 80% Today?
IsoPlexis (NASDAQ: ISO ) stock is jumping more than 80% today on news that the company will join forces with Berkeley Lights (NASDAQ: BLI ). The two names will combine into a new company called PhenomeX.
2022-11-11 13:57:04 - Seeking Alpha
IsoPlexis Corporation (ISO) Q3 2022 Earnings Call Transcript
IsoPlexis Corporation (NASDAQ:ISO ) Q3 2022 Earnings Conference Call November 10, 2022 5:30 PM ET Company Participants Carrie Mendivil - IR Sean Mackay - CEO John Strahley - CFO Conference Call Participants Jordan Adler - Evercore ISI Joe Giordano - Cowen Michael Jones - SVB Securities Edmund Tu - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the IsoPlexis Third Quarter 2022 Earnings Conference Call.
2022-11-09 07:00:00 - GlobeNewsWire
IsoPlexis to Participate in Upcoming Investor Conferences
BRANFORD, Conn., Nov. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the following investor conferences.
2022-10-19 07:00:00 - GlobeNewsWire
IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022
BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
2022-08-31 07:00:00 - GlobeNewsWire
IsoPlexis to Participate in the Morgan Stanley Global Healthcare Conference
BRANFORD, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
2022-08-10 15:24:07 - Seeking Alpha
IsoPlexis Corporation (ISO) CEO Sean Mackay on Q2 2022 Results Earnings Call Transcript
IsoPlexis Corporation (NASDAQ:ISO ) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Carrie Mendivil - IR Sean Mackay - CEO John Strahley - CFO Conference Call Participants Vijay Kumar - Evercore Max Masucci - Cowen Puneet Souda - SVB Leerink Tejas Savant - Morgan Stanley Operator Good morning ladies and gentlemen, thank you for standing by. And welcome to IsoPlexis' Second Quarter 2022 Earnings Conference Call.
2022-07-21 07:00:00 - GlobeNewsWire
IsoPlexis to Report Second Quarter 2022 Financial Results on August 10, 2022
BRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the second quarter 2022 before market open on Wednesday, August 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
2022-04-08 07:00:00 - GlobeNewsWire
IsoPlexis to Present First-of-Its-Kind Data on Simultaneous Single Cell TCR Profiling and Highly Multiplexed Functional Proteomics at AACR 2022
IsoLight and Duomic Technologies Detect T Cell Receptors and Highly Multiplexed Functional Cytokines from the Same Single Cells to Advance Cancer Immunology Discovery IsoLight and Duomic Technologies Detect T Cell Receptors and Highly Multiplexed Functional Cytokines from the Same Single Cells to Advance Cancer Immunology Discovery
2022-03-02 13:37:09 - Seeking Alpha
IsoPlexis' (ISO) CEO Sean Mackay on Q4 2021 Results - Earnings Call Transcript
2022-02-16 07:00:00 - GlobeNewsWire
IsoPlexis to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022
BRANFORD, Conn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the fourth quarter and full year 2021 before market open on Wednesday, March 2, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.